Blue Barn Wealth LLC Makes New Investment in IDEXX Laboratories, Inc. $IDXX

Blue Barn Wealth LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 2nd quarter, HoldingsChannel reports. The firm acquired 420 shares of the company’s stock, valued at approximately $225,000.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in IDEXX Laboratories by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 9,855,937 shares of the company’s stock worth $4,139,001,000 after buying an additional 146,427 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in IDEXX Laboratories by 71.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock worth $835,244,000 after buying an additional 825,965 shares in the last quarter. Bank of New York Mellon Corp increased its stake in IDEXX Laboratories by 156.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock worth $778,439,000 after buying an additional 884,808 shares in the last quarter. Invesco Ltd. increased its stake in IDEXX Laboratories by 0.5% during the 1st quarter. Invesco Ltd. now owns 1,166,406 shares of the company’s stock worth $489,832,000 after buying an additional 5,418 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in IDEXX Laboratories by 37.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,076,429 shares of the company’s stock worth $452,046,000 after buying an additional 290,551 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Sharon E. Underberg sold 5,450 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president directly owned 6,156 shares in the company, valued at approximately $4,011,249.60. This represents a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the transaction, the executive vice president owned 11,287 shares in the company, valued at $7,336,098.52. This represents a 3.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 9,243 shares of company stock valued at $6,018,650. Insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on IDXX. UBS Group boosted their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a report on Monday. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Finally, Piper Sandler restated a “neutral” rating and set a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $730.50.

IDEXX Laboratories Trading Down 0.1%

IDXX opened at $722.12 on Wednesday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $735.00. The stock has a market capitalization of $57.77 billion, a PE ratio of 60.13, a P/E/G ratio of 4.06 and a beta of 1.58. The business’s 50 day moving average price is $641.13 and its 200 day moving average price is $574.15. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.40 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.26. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the firm posted $2.80 earnings per share. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.